Bavencio 200mg Injection 10ml

Bavencio 200mg/10ml injection contains the active ingredient avelumab. It is an antineoplastic drug that belongs to the class of medications called PD-1/PD-L1 (programmed death ligand-1) inhibitors. It is used to treat Merkel cell carcinoma, a rare type of skin cancer that has spread to other body parts in adults and children 12 years and older. It is also indicated to treat urothelial carcinoma, cancer that originates in the urinary tract that has spread to nearby tissues or other body parts of the body in people whose cancer worsened during or within 12 months after it was treated with other anticancer medications.

It is also used in combination with other anticancer medicines to treat renal cell carcinoma, a type of kidney cancer that has spread to other body parts. PD-L1 is found on the surface of certain cancer cells and helps protect them from the immune system. It works by slowing or stopping the growth and spread of the cancer cells.  Do not take Bavencio 200mg/10ml injection if you are allergic to avelumab or any other ingredients of this medicine. Inform your physician if you have liver diseases, hepatitis B, HIV/AIDS, or other immune diseases before initiating the therapy.

This medicine is not recommended for children and adolescents below 18. If you suffer from any of the reactions like infusion-related reactions, inflammation of your lungs, liver, pancreas, watery stools, or diarrhea, inform your doctor immediately and seek medical attention. Bavencio 200mg/10ml injection should not be used in pregnant and breastfeeding women. Inform your physician if you are pregnant or breastfeeding. Use effective contraception throughout the therapy to avoid pregnancy. The common adverse reactions are tiredness, muscle pain, diarrhea, nausea, rash, decreased appetite, urinary tract infection, and swelling in the body parts.